BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS. Biomarkers for hepatocellular cancer. World J Hepatol 2020; 12(9): 558-573 [PMID: 33033565 DOI: 10.4254/wjh.v12.i9.558] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Ruiz-manriquez LM, Carrasco-morales O, Sanchez Z EA, Osorio-perez SM, Estrada-meza C, Pathak S, Banerjee A, Bandyopadhyay A, Duttaroy AK, Paul S. MicroRNA-mediated regulation of key signaling pathways in hepatocellular carcinoma: A mechanistic insight. Front Genet 2022;13:910733. [DOI: 10.3389/fgene.2022.910733] [Reference Citation Analysis]
2 Li J, Li N, Azhar MS, Liu L, Wang L, Zhang Q, Sheng L, Wang J, Feng S, Qiu Q, Xiao Y. Analysis of mutations in DNA damage repair pathway gene in Chinese patients with hepatocellular carcinoma. Sci Rep 2022;12:12330. [PMID: 35853969 DOI: 10.1038/s41598-022-16604-6] [Reference Citation Analysis]
3 Mir IH, Jyothi KC, Thirunavukkarasu C. The prominence of potential biomarkers in the diagnosis and management of hepatocellular carcinoma: Current scenario and future anticipation. J Cell Biochem 2021. [PMID: 34897788 DOI: 10.1002/jcb.30190] [Reference Citation Analysis]
4 Zamora-León SP. Hepatocellular carcinoma biomarkers, an imminent need. World J Gastrointest Oncol 2021; 13(11): 1847-1849 [PMID: 34853655 DOI: 10.4251/wjgo.v13.i11.1847] [Reference Citation Analysis]
5 Evangelista J, Zaninotto E, Gaglio A, Ghidini M, Raimondi L. MicroRNAs as Diagnostic Tools in Hepatocellular Carcinoma. GastrointestDisord 2021;3:237-46. [DOI: 10.3390/gidisord3040022] [Reference Citation Analysis]
6 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Reference Citation Analysis]
7 Liu Y, Chen Y, Fei W, Zheng C, Zheng Y, Tang M, Qian Y, Zhang X, Zhao M, Zhang M, Wang F. Silica-Based Nanoframeworks Involved Hepatocellular Carcinoma Theranostic. Front Bioeng Biotechnol 2021;9:733792. [PMID: 34557478 DOI: 10.3389/fbioe.2021.733792] [Reference Citation Analysis]
8 Canale M, Foschi FG, Andreone P, Ercolani G, Marisi G, Conti F, Vukotic R, Guarneri V, Burgio V, Ratti F, Aldrighetti L, De Cobelli F, Cascinu S, Ulivi P, Casadei-Gardini A. Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery. HPB (Oxford) 2021:S1365-182X(21)00603-1. [PMID: 34366240 DOI: 10.1016/j.hpb.2021.06.421] [Reference Citation Analysis]
9 Jun SY, Yoon HR, Yoon JY, Jeon SJ, Lee JJ, Halder D, Kim JM, Kim NS. The Human TOR Signaling Regulator Is the Key Indicator of Liver Cancer Patients' Overall Survival: TIPRL/LC3/CD133/CD44 as Potential Biomarkers for Early Liver Cancers. Cancers (Basel) 2021;13:2925. [PMID: 34208132 DOI: 10.3390/cancers13122925] [Reference Citation Analysis]
10 Moldogazieva NT, Zavadskiy SP, Terentiev AA. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine. Cancer Genomics Proteomics 2021;18:369-83. [PMID: 33994362 DOI: 10.21873/cgp.20266] [Reference Citation Analysis]
11 Ren X, Li A, Ying E, Fang J, Li M, Yu J. Upregulation of ubiquitin-conjugating enzyme E2T (UBE2T) predicts poor prognosis and promotes hepatocellular carcinoma progression. Bioengineered 2021;12:1530-42. [PMID: 33934686 DOI: 10.1080/21655979.2021.1918507] [Reference Citation Analysis]